IBN SINA Pharma Announces AGM, Posts Solid Profits Despite EPS Dip
IBN SINA Pharmaceuticals, a prominent drug manufacturer listed on the Dhaka Stock Exchange since 1989, has announced its annual general meeting (AGM) for 23 November 2025. Shareholders should note the record date of 26 October 2025 for this digital event.
The company's standalone performance in the fiscal year 2024-25 showed a net profit of Tk66.02 crore, translating to earnings per share (EPS) of Tk21.13. However, the consolidated EPS stood at Tk20.27, down from Tk21.46 in the previous year. Similarly, the consolidated net profit decreased by 5.55% to Tk63.33 crore. Despite these fluctuations, the company's net asset value (NAV) per share remained strong at Tk125.86 as of June 2025.
IBN SINA Pharmaceuticals, established in 1983, produces a wide range of drugs, including herbal and Unani medicines. Its manufacturing facilities in Gazipur are equipped with advanced technology. The company has recommended a 64% cash dividend for the 2024-25 fiscal year. As of 30 September 2025, the company's share price closed at Tk307.30 on the Dhaka Stock Exchange.
IBN SINA Pharmaceuticals' AGM is set for 23 November 2025, with shareholders urged to mark their calendars by the record date of 26 October 2025. Despite a slight dip in consolidated earnings, the company's standalone profits and net asset value per share remain robust. With a recommended 64% cash dividend, shareholders can anticipate a solid return on their investments.
Read also:
- Trade Disputes Escalate: Trump Imposes Tariffs, India Retaliates; threatened boycott ranges from McDonald's, Coca-Cola to iPhones
- Aquatech purchases Koch's Direct Lithium Extraction business, merging Li-ProTM DLE technology into the PEARLTM Technology Platform.
- Nepal's Journey: Evolution from Street Life to Political Power
- Li Auto faces scrutiny after crash test involving i8 model and a truck manufacturer sparks controversy
